Background and Purpose-Homozygous and compound heterozygous mutations in the high temperature requirement serine peptidase A1 gene (HTRA1) cause cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. However, heterozygous HTRA1 mutations were recently identified to be associated with autosomal dominant cerebral small vessel disease (SVD). The present study aims at investigating the clinical features, frequency, and spectrum of HTRA1 mutations in a Taiwanese cohort with SVD. Methods-Mutational analyses of HTRA1 were performed by Sanger sequencing in 222 subjects, selected from a cohort of 337 unrelated patients with SVD after excluding those harboring a NOTCH3 mutation. The influence of these mutations on HTRA1 protease activities was characterized. Results-Seven novel heterozygous mutations in HTRA1 were identified, including p.Gly120Asp, p.Ile179Asn, p.Ala182Profs*33, p.Ile256Thr, p.Gly276Ala, p.Gln289Ter, and p.Asn324Thr, and each was identified in 1 single index patient. All mutations significantly compromise the HTRA1 protease activities. For the 7 index cases and another 2 affected siblings carrying a heterozygous HTRA1 mutation, the common clinical presentations include lacunar infarction, intracerebral hemorrhage, cognitive decline, and spondylosis at the fifth to sixth decade of life. Among the 9 patients, 4 have psychiatric symptoms as delusion, depression, and compulsive behavior, 3 have leukoencephalopathy in anterior temporal poles, and 2 patients have alopecia. 
C erebral small vessel disease (SVD) encompasses a heterogeneous group of diseases with pathological processes affecting the small arteries, arterioles, venules, and capillaries of brain. SVD is now recognized as a major cause of stroke and vascular dementia and a strong predictor of disability and mortality in the elderly population. 1 Making molecular diagnosis in patients with SVD is challenging because sporadic and hereditary SVD share similar phenotypes, and the monogenic forms account for only 5% of overall SVD. 2 Genetic mutations frequently implicated in familial SVD include NOTCH3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), TREX1 mutations in retinal vasculopathy with cerebral leukodystrophy, and mutations in the high-temperature requirement protease A1 gene (HTRA1) in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). [3] [4] [5] CARASIL is a rare SVD caused by biallelic mutations in HTRA1. 6 The eponym of CARASIL signifies its nature of recessive inheritance and clinical resemblance to CADASIL. 5 There have been only 15 CARASIL families reported to date, and most of them are consanguineous families. [6] [7] [8] [9] [10] [11] [12] [13] [14] However, a recent study disclosed that heterozygous HTRA1 mutations could manifest as autosomal dominant SVD. 15 Up to 5% of hereditary SVD in the European population was found to be attributed to heterozygous HTRA1 mutations. 15 The causative role of heterozygous HTRA1 mutations in autosomal dominant SVD was also validated in another Japanese cohort, in which 4 heterozygous HTRA1 mutations were detected in 6 index patients after screening 113 unrelated SVD cases for HTRA1 mutations. 16 In addition, 5 of 142 unrelated Italian patients with familial SVD were found to harbor a heterozygous mutation in HTRA1. 17 These evidences support that both homozygous and heterozygous HTRA1 mutations may cause
Stroke
July 2018
SVD, and the prevalence of HTRA1-related SVD has been underestimated before. The present study aims at delineating the clinical characteristics, frequency, and spectrum of HTRA1 mutations in a Taiwanese cohort with SVD. Mutational analyses of HTRA1 were performed in 222 persons, selected from a cohort of 337 unrelated SVD patients after excluding those with a NOTCH3 mutation. The influence of the identified HTRA1 mutations on HTRA1protease activities was also investigated in vitro.
Methods
Anonymized data have been made publicly available at the ClinVar and can be accessed at https://www.ncbi.nlm.nih.gov/clinvar/.
Subjects
A consecutive series of 337 unrelated cases with SVD were enrolled from the Neurology Department of Taipei Veterans General Hospital between 2000 and 2015. The inclusion criteria were subjects with (1) marked leukoencephalopathy defined as Fazekas grade 2 or grade 3 on neuroimaging, 18 and (2) at least one of the following features: lacunar infarction, transient ischemic attack, cognitive dysfunction, psychiatric disorder, gait disturbance, or a family history of ischemic stroke or vascular dementia. Among the 337 patients with SVD, 115 had a NOTCH3 mutation and were diagnosed to have CADASIL. 19 These 115 patients with CADASIL were excluded from further genetic survey, leading to a total of 222 SVD subjects in the study cohort. In addition, 500 individuals free of stroke or dementia were enrolled as ethnically matched controls. All participants were of HanChinese descent. Peripheral blood samples were collected after written informed consent was obtained. This study was approved by the Institutional Review Board of Taipei Veterans General Hospital.
Magnetic Resonance Imaging (MRI)
Demographic and clinical information was obtained from patients and medical records. The severity of white matter hyperintensity was quantified on T2-weighted images or fluid-attenuated inversion recovery sequences of brain MRI while cerebral microbleeds were analyzed on T2*-weighted gradient-recalled echo or susceptibilityweighted sequences. 20 The modified Scheltens Scales was used to rate white matter hyperintensity at both sides of corona radiata, external capsules, and anterior temporal poles separately.
21,22

Mutational Analyses
Genomic DNA was extracted from peripheral blood cells. The coding regions of HTRA1 were amplified by polymerase chain reaction using intronic primers (Table I in the online-only Data Supplement). All amplicons were sequenced using the Big Dye 3.1 dideoxy terminator method (Applied Biosystems, Foster City, CA) on an ABI Prism 3700 Genetic Analyzer (Applied Biosystems). Amplicon sequences were compared with the reference sequence of HTRA1 (GRCh38, NM_002775.4).
The pathogenicity of the identified variants was determined by their absence in 500 neurologically healthy individuals of Han-Chinese origin and bioinformatics prediction. We also queried the Genome Aggregation Database, which includes 123 136 exome and 15 496 genome data from unrelated individuals of various populations (http://gnomad.broadinstitute.org). 23 Functional impact of the putative HTRA1 mutations was predicted using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), 24 Mutation Taster (http://www.mutationtaster.org), 25 and Combined Annotation Dependent Depletion (http://cadd.gs.washington. edu). 26 Evolutionary conservation of the amino acids at mutation sites was analyzed by aligning sequences of HTRA1 orthologs of multiple species.
In Vitro Functional Study
Please see Methods in the online-only Data Supplement.
Results
Heterozygous HTRA1 Mutations in Taiwanese Patients With SVD
Among the 222 unrelated patients with molecularly unassigned SVD, we initially found 9 heterozygous variants in HTRA1. Among them, p.Arg59Pro and p.Val149Ala were unlikely to be pathogenic for their presence in the 500 Taiwanese healthy controls with allele frequencies of 0.8% and 0.1%, respectively. Six of the remaining HTRA1 mutations were absent in both the 500 Taiwanese healthy controls and Genome Aggregation Database, including 4 missense mutations (p.Gly120Asp, p.Ile179Asn, p.Gly276Ala, and p.Asn324Thr), 1 nonsense mutation (p.Gln289Ter), and 1 frameshift mutation (p.Ala182Profs*33). The last 1 HTRA1 mutation, p.Ile256Thr, was present in Genome Aggregation Database with an extremely low allele frequency of 0.000008 and was not present in our 500 ethnically matched controls.
All the 7 HTRA1 heterozygous mutations were predicted to be pathogenic by Mutation Taster and PolyPhen-2 (Table 1) . 24, 25 The Combined Annotation Dependent Depletion v1.2 Phred scores of these mutations ranged from 21.6 to 42, ranking them in the top 6.9/1000 to 6.3/100 000 most deleterious variants in the genome. 26 Among the 7 mutations, p.Ala182Profs*33 and p.Gln289Ter result in HTRA1 truncation which leads to complete or partial loss of the serine protease domain. HTRA1 p.Ile256Thr, p.Gly276Ala, and p.Asn324Thr alter amino acids residing within the protease domain while p.Gly120Asp and p.Ile179Asn affect residues within or close to the Kazal-type serine protease inhibitor domain ( Figure 1A ). The amino acids influenced by these 5 missense mutations are all evolutionally conserved across HTRA1 orthologs from human to zebrafish ( Figure 1B ).
The 7 heterozygous HTRA1 mutations have not been reported before. Each mutation was identified in 1 proband, suggesting 2.08% (7 of 337) of SVD patients in the Han-Chinese population in Taiwan was attributed to a 
In Vitro Analyses of HTRA1 Protease Activity
To assess the functional consequences of the HTRA1 mutations, we first transfected human embryonic kidney cells 293 with empty vector, wide-type (WT), or either one of the mutant HTRA1 expression plasmids and investigated the expression levels of WT or the HTRA1 mutants by Western blotting. It showed that the expression levels of WT and the 5 missense mutant HTRA1 proteins were similar at steady state ( Figure I in the online-only Data Supplement). However, the p.Ala182Profs*33 and p.Gln289Ter mutations resulted in a smaller, truncated protein product with a lower expression level. HTRA1 is a serine protease that regulates the TGF-β (transforming growth factor β) signaling pathway through cleavage of proTGF-β1, TGF-β dimers, and TGF-β receptors. 27, 28 To assess the influence of these HTRA1 mutations, the enzymatic activities of WT or either one of the mutant HTRA1 proteins to hydrolyze fluorescein isothiocyanatelabeled casein were measured. The HTRA1 protease activities of the 7 HTRA1 mutants were significantly lower than that of WT HTRA1 (Figure 1C; all P<0.001) . Noticeably, the p.Ala182Profs*33 and p.Gln289Ter mutations resulted in a complete loss of protease activity comparable to that of the enzymatically inactive p.Ser328Ala mutation.
To investigate whether the 7 HTRA1 mutations exerted a dominant-negative effect on the HTRA1 enzymatic function, we assayed the protease activities of HTRA1 proteins purified from human embryonic kidney cells 293 transfected with half-dose of WT and half-dose of one of the mutant HTRA1 expression plasmids or empty vector. Compared with that in the cells transfected with half-dose of WT HTRA1 expression plasmids and half-dose of empty vector, the HTRA1 protease activities were significantly lower only in the cells coexpressing both WT and either one of p.Ala182Profs*33, p.Ile256Thr, and p.Gln289Ter Figure 1D ; all P<0.05). These findings suggested that these 3 heterozygous HTRA1 mutations not only disturbed their own protease activities but also hampered the function of WT HTRA1. For the other 4 HTRA1 mutations (p.Gly120Asp, p.Ile179Asn, p.Gly276Ala, and p.Asn324Thr), the mutant proteins had impaired enzymatic activities but did not affect the WT proteins.
HTRA1 mutants (
Clinical Features of Patients With a Heterozygous HTRA1 Mutation
We found 9 patients (7 probands and 2 affected siblings) carrying a heterozygous HTRA1 mutation. The clinical characteristics and pedigree are illustrated in Table 2 and Figure 2 . The average age at symptom onset was 54.8±7.3 years. Stroke and cognitive dysfunction were the Figure 2 . The pedigrees and electropherograms of the heterozygous HTRA1 mutations. Open symbol, unaffected; filled symbol, affected; symbol with a diagonal line, deceased; square, males; circle, females; and arrowhead, the proband.
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July 2018 core manifestations. Seven of the 9 patients (77.8%) had cerebrovascular events, including 5 patients with lacunar infarction and 2 diagnosed with transient ischemic attack. Intriguingly, 3 patients had both ischemic and hemorrhagic strokes. One patient experienced advanced dementia, 2 developed mild cognitive dysfunction, and 3 patients had subjective complaints of mentality decline. The percentage of psychiatric disorders was unexpectedly high with 4 of the 9 patients having depression or psychotic symptoms. Seven patients had spinal spondylosis or herniated discs at cervical-or lumbar-spines at diagnosis. Hair thinning was noted in patient VI-1 and her elder brother (patient VI-2), and both of them carried a HTRA1 p.Gln289Ter mutation. The clinical presentations of individual patients harboring a heterozygous HTRA1 mutation are described in data in the online-only Data Supplement. All of the 9 patients had moderate or severe leukoencephalopathy, and 3 patients (30%) developed anterior temporal pole involvement (Table 3) . Cerebral microbleeds were detected in 3 of the 6 patients (50%) in whom T2*-weighted gradient-recalled echo or susceptibility-weighted sequences of brain MRI were available. Figure 3 shows the representative neuroimages of patient III-1, IV-1, and VI-1 carrying a heterozygous HTRA1 p.Ala182Profs*33, p.Ile256Thr, and p.Gln289Ter, respectively.
Discussion
Before this study, there have been 12 homozygous mutations, 1 compound heterozygous mutation, and 23 single heterozygous mutations in HTRA1 in the literature ( Figure 1A) . [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [29] [30] [31] The present study expands the mutational spectrum of HTRA1-related SVD with 7 novel heterozygous mutations and delineates the clinical and neuroradiological features of Han-Chinese patients with heterozygous HTRA1 mutations. The pathogenicity of these 7 heterozygous HTRA1 mutations can be well supported by the following lines of evidence. First, all these mutations are absent in 500 ethnically matched controls. Six mutations have never been reported in the public genomic database, and the other one mutation occurs with a low frequency, leading to a statistically increased prevalence of heterozygous HTRA1 mutations in the patients with SVD than that in the individuals in Genome Aggregation Database (Fisher exact test, P=0.0016-0.0053). Second, all the 7 mutations are predicted to be pathogenic by multiple bioinformatics tools, and 2 of them result in truncation of the protein product. Third, the amino acid residues altered by these mutations are located within domains critical for HTRA1 functioning and are evolutionally conserved across species at least from human to fish. Forth, in vitro study demonstrates that all these mutations lead to partial or complete loss of HTRA1 protease activities, and 3 mutations (p.Ala182Profs*33, p.Ile256Thr, and p.Gln289Ter) may additionally exert a dominant-negative effect on the enzymatic function of WT HTRA1. Last, for the pedigree II and VI, family members who carry the heterozygous HTRA1 mutations also develop symptoms akin to the index cases. Therefore, these 7 heterozygous HTRA1 mutations can be classified as pathogenic or likely pathogenic according to the guideline of the American College of Medical Genetics and Genomics. 32 Our study supports that compromised HTRA1 protease activity is a prerequisite for a heterozygous HTRA1 mutation to cause autosomal dominant SVD. Verdura et al 15 analyzed 7 heterozygous HTRA1 mutations and found all of them leading to a significantly impaired HTRA1 protease activity. Nozaki et al 16 revealed that the 4 heterozygous HTRA1 mutations found in their patients with SVD exhibited both direct deleterious and dominant-negative effects on HTRA1 enzymatic activity. We also showed that the 7 heterozygous HTRA1 mutations carried by Taiwanese patients with SVD resulted in a completely or partially abolished HTRA1 protease activity. Although the exact mechanism responsible for a single heterozygous HTRA1 mutation to cause SVD is still not fully clear, impaired HTRA1 protease function seems to be a core feature of HTRA1-related autosomal dominant SVD, and relevant in vitro functional assays may help to evaluate the pathogenicity of HTRA1 variants.
Because deficiency of HTRA1 protease activity due to recessive loss-of-function HTRA1 mutations is the cause of CARASIL, the dominant-negative effect of some HTRA1 mutations, which can also lead to depletion of HTRA1 enzymatic activity by inhibiting WT HTRA1 function, can be a sufficient condition to result in autosomal dominant SVD. However, the dominant-negative effect may not be indispensable for every heterozygous HTRA1 mutation to cause SVD. Among the 7 mutations identified in this study, all are associated with a compromised HTRA1 enzymatic function. The lower expression level of p.Ala182Profs*33 and p.Gln289Ter mutations on Western blotting indicates these 2 mutations may be submitted to nonsense mediated mRNA decay; regrettably, we were not able to obtain the samples for cDNA analysis. These 2 mutations as well as p.Ile256Thr may have additional dominant-negative effects because the WT HTRA1 enzymatic activities were attenuated by mutant proteins in the cotransfection study. Interestingly, the patients carrying each of these 3 mutations have a more severe and widespread leukoencephalopathy compared with that of the patients harboring a mutation without the dominant-negative effect (Table 3 ; Figure 3 ). These findings can be well explained by that different degrees of HTRA1 protease activity deficiency result in SVD of various severities, and a heterozygous HTRA1 mutation with a loss-of-function feature but no dominant-negative effect may cause SVD with a milder manifestation. From previous CARASIL studies, although the parents carrying a heterozygous mutation of HTRA1 p.Glu42fs, p.Gly295Arg, or p.Arg321Thr did not develop profound dementia or young stroke as their affected homozygous offspring, they also had leukoencephalopathy, 8, 31 indicating that they had a mild form of SVD. The phenomenon that different severities of genetic defect result in corresponding clinical severities also has been observed in diseases associated with glucosylceramidase beta gene (GBA), in which homozygous mutations cause adolescent onset, rapidly progressive neurological deterioration whereas heterozygous carriers present as late onset Parkinson disease. 33, 34 Another example is a group of newly identified diseases attributed to PUM1 mutation. 35 A mild PUM1 mutation reducing PUM1 protein levels by 25% is associated with adult-onset ataxia. However, PUM1 mutations lowering PUM1 protein levels by 50% cause infantile-onset disease with developmental delay, ataxia, and seizure. 35 The current study is the largest 1 among the 4 SVD cohorts investigating heterozygous HTRA1 mutations. [15] [16] [17] After excluding patients carrying a pathogenic mutation in NOTCH3, we found that 5.61% (6 of 107) of familial SVD in the Han-Chinese population was caused by a heterozygous HTRA1 mutation, comparable to the prevalence of 6.52%, 4.98%, 3.52% reported in the Japanese, European, and Italian patients with familial SVD, respectively. [15] [16] [17] To summarize the findings from the different ethnic groups, recurrent stroke and cognitive decline at the fifth to sixth decade of life are the main features of patients harboring a heterozygous HTRA1 mutation. Although intracerebral hemorrhage has never been reported in patients with a heterozygous HTRA1 mutation before, 3 patients in this study have both ischemic and hemorrhagic strokes. In addition, cerebral microbleeds are detected in one third of the European patients and 3 of our patients
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carrying a heterozygous HTRA1 mutation, 15 suggesting the risk of hemorrhagic stroke may be underestimated. Furthermore, psychiatric disorder seems to be a common but overlooked comorbidity because 44.4% of the Taiwanese patients with a heterozygous HTRA1 mutation experience mood or psychotic symptoms. Similarly, one third of CARASIL patients harboring biallelic mutations in HTRA1 is found to have mood disorders. 14 Noticeably, screening for HTRA1 mutations is not only important for familial SVD but also worthy in SVD patients without a family history. Nozaki et al 16 demonstrated that 3 of the 67 Japanese patients with sporadic SVD had a heterozygous HTRA1 mutation. We also identified a heterozygous HTRA1 mutation in 1 of the 115 Taiwanese SVD patients without family history of SVD and a NOTCH3 mutation. Moreover, unlike CARASIL patients developing motor and mental disturbance at age 30 years, 14 the age of disease onset of patients carrying a single heterozygous HTRA1 mutation ranges from 51.6 to 61.3 years. [15] [16] [17] Although in our cohort, the average age of onset of the patients carrying a heterozygous HTRA1 mutation is significantly earlier than that of the patients with sporadic SVD, the ranges of the onset age overlap between the 2 groups. Thus, it is still difficult to discriminate SVD patients with or without a heterozygous HTRA1 mutation by age of disease onset only. Alopecia, detected in 90% of patients with homozygous or compound heterozygous HTRA1 mutations, 4 occurs in less than one third of patients with a heterozygous HTRA1 mutation. 16 Obvious spondylosis or intervertebral herniated discs is a common presentation in patients with a heterozygous HTRA1 mutation at diagnosis. Presence of leukoencephalopathy in the anterior temporal poles is not a reliable sign to distinguish HTRA1-related SVD from CADASIL because patients with biallelic mutations or a heterozygous mutation in HTRA1 may also have this feature. 5, 21 Except for more familial cases, the clinical and neuroimaging characteristics of SVD caused by a heterozygous HTRA1 mutation resemble to those of other SVD patients with unknown molecular diagnosis in our cohort (Table II in 
Summary
The present study expands the mutational spectrum of heterozygous HTRA1 mutations in patients with SVD and comprehensively addresses their clinical and neuroimaging characteristics. The clinical manifestations, presence of extraneurological features or not, white matter hyperintensity with anterior temporal pole involvement on MRI, and severity of leukoencephalopathy are not reliable clues to differentiate HTRA1-related SVD from other SVD. For SVD patients without a NOTCH3 mutation, heterozygous HTRA1 mutations account for 3.5% to 6.5% of familial cases and 0.8% to 4.4% of sporadic SVD worldwide. Our findings strengthen the importance of mutational analyses of HTRA1 in patients with familial or sporadic SVD with unknown pathogenesis.
